fashion -WSS

fashion

author：focus 2025-09-28 23:30:47 - browse：527

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Why Medicare shouldn’t cover every FDA

WSS

NIH study of ME/CFS points to clear biological hallmarks

STAT readers on older presidents, polypills, Medicare, and more

Medicare Advantage insurers face 0.2% cut to 2025 payments

Vertex non

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: The latest on Novavax, Merck, Bluebird

leisure time

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Philips to halt sales of sleep apnea machines in U.S.

Trump demands the U.S. pay no more for drugs than other countries … again

Humana’s losses in Medicare Advantage tank its stock

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare drug price negotiation legal challenge met with skepticism

Medical leaders decry Supreme Court decision on affirmative action

STAT readers on older presidents, polypills, Medicare, and more

BioMarin wins approval for gene therapy to treat hemophilia A

Pancreatic cancer early detection could be helped by AI

explore

Zyn nicotine pouches become unlikely player in latest culture war

A new nitrogen execution bill also undermines medical licensing

Why you shouldn’t ask, “What country has the best health care?”

White House pharmacy plagued with problems, investigation finds

Philips to halt sales of sleep apnea machines in U.S.

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

leisure time

hotspot

knowledge

leisure time